CR20220332A - Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias - Google Patents

Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias

Info

Publication number
CR20220332A
CR20220332A CR20220332A CR20220332A CR20220332A CR 20220332 A CR20220332 A CR 20220332A CR 20220332 A CR20220332 A CR 20220332A CR 20220332 A CR20220332 A CR 20220332A CR 20220332 A CR20220332 A CR 20220332A
Authority
CR
Costa Rica
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Application number
CR20220332A
Other languages
English (en)
Inventor
Ashok Bhandari
Danila Branca
Raymond Patch
Roberto Costante
Sandeep Somani
Raffaele Ingenito
Elisabetta Biachi
Chengzao Sun
Brian Troy Frederick
Gregory Thomas Bourne
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of CR20220332A publication Critical patent/CR20220332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona nuevos péptidos inhibidores del receptor de interleucina-23 y composiciones y métodos relacionados para usar estos inhibidores de péptidos para tratar o prevenir una variedad de enfermedades y trastornos, incluidas las enfermedades inflamatorias del intestino
CR20220332A 2020-01-15 2021-01-14 Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias CR20220332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961624P 2020-01-15 2020-01-15
PCT/US2021/013463 WO2021146441A1 (en) 2020-01-15 2021-01-14 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
CR20220332A true CR20220332A (es) 2022-11-28

Family

ID=76864704

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220332A CR20220332A (es) 2020-01-15 2021-01-14 Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias

Country Status (20)

Country Link
US (2) US11845808B2 (es)
EP (1) EP4090670A1 (es)
JP (2) JP7441955B2 (es)
KR (1) KR20220141807A (es)
CN (5) CN118005737A (es)
AR (1) AR121070A1 (es)
AU (1) AU2021207653A1 (es)
BR (1) BR112022013957A2 (es)
CA (1) CA3167751A1 (es)
CL (1) CL2022001893A1 (es)
CO (1) CO2022009931A2 (es)
CR (1) CR20220332A (es)
DO (1) DOP2022000147A (es)
EC (1) ECSP22063238A (es)
IL (1) IL294680A (es)
JO (1) JOP20220169A1 (es)
MX (1) MX2022008741A (es)
PE (1) PE20230370A1 (es)
TW (1) TW202140517A (es)
WO (1) WO2021146441A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
RU2736637C9 (ru) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3997105A4 (en) * 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
CN118005737A (zh) 2020-01-15 2024-05-10 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
CA3202226A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CA3226532A1 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
WO2023004414A1 (en) * 2021-07-23 2023-01-26 Colorado Chromatography, Llc A method for preparing hexahydrocannabinol
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023150500A1 (en) 2022-02-01 2023-08-10 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof
WO2023177452A1 (en) * 2022-03-14 2023-09-21 Colorado Chromatography, Llc Hydrogenation of cannabigerol and cannabichromene
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (ja) 1989-05-01 1990-12-20 Monsanto Co キラルβ―アミノ酸の製造方法
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
CA2106314A1 (en) 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
ATE235911T1 (de) 1992-11-12 2003-04-15 Sod Conseils Rech Applic Opioidpeptide
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
EP0998309A1 (en) 1997-07-11 2000-05-10 Innerdyne Medical, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
CA2309338A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
EP1100473A2 (en) 1998-07-28 2001-05-23 InnerDyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
AU3273500A (en) 1999-03-17 2000-10-04 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
HUP0200803A3 (en) 1999-04-12 2002-12-28 Aventis Pharma Ltd West Mallin Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002055106A2 (en) 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004058307A1 (en) 2002-12-18 2004-07-15 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
AU2004231122B2 (en) 2003-04-15 2010-04-08 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
CA2544223C (en) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1695255B1 (en) 2003-12-19 2016-09-07 Applied Biosystems, LLC Methods and systems for protein and peptide evidence assembly
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
EP1781689A4 (en) 2004-06-24 2010-11-10 Inst Medical W & E Hall CONJUGATES AND THEIR THERAPEUTIC APPLICATIONS
WO2006032104A1 (en) 2004-09-23 2006-03-30 The University Of Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20080300180A1 (en) 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US8076306B2 (en) 2006-04-12 2011-12-13 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
KR101399175B1 (ko) 2006-07-21 2014-06-19 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 항염증성 및 항알레르기성 시클릭 펩티드
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
WO2008140602A2 (en) 2006-12-07 2008-11-20 The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN
JP2010517529A (ja) 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド ヘプシジン及びヘプシジン抗体
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US8313950B2 (en) 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
US20100190710A1 (en) 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CN101358201A (zh) 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
CA2741566A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US9328140B2 (en) 2008-12-05 2016-05-03 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
US8435941B2 (en) 2008-12-05 2013-05-07 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
CA2758264A1 (en) 2009-04-08 2010-10-14 Takeda Pharmaceutical Company Limited Neuromedin u derivative
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2733150A1 (en) 2010-01-25 2014-05-21 Cornell University Aromatic-cationic peptides and uses of same
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
JP2011231085A (ja) 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
US20130236977A1 (en) 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
SI2603232T1 (sl) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
CA2839408A1 (en) 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2013177432A1 (en) 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP2956154A4 (en) 2013-02-15 2016-07-27 Srx Cardio Llc TYPE 9 (PCSK9) PROPYTEIN CONVERTASE SUBTILISINE / KEXINE PROPAGINE CONVERTASE BINDING LIGANDS FOR USE IN MODULATION OF SERIES LEVELS OF LOW DENSITY LIPOPROTEIN (LDL)
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
RS60180B1 (sr) 2013-06-24 2020-06-30 Canbas Co Ltd Kombinovana upotreba peptida i peptidomimetika i tretman subpopulacija pacijenata obolelih od kancera
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
WO2015054500A2 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
CN106456703A (zh) 2014-04-07 2017-02-22 摩坚瑟生物技术股份有限公司 铁调素模拟肽及其用途
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
CA2953721A1 (en) 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
RU2736637C9 (ru) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
JP2018508466A (ja) 2014-12-29 2018-03-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｓ−アルキル化ヘプシジンペプチドならびにその作製及び使用方法
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3341011A4 (en) * 2015-07-15 2019-02-20 Protagonist Therapeutics Inc. PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018022917A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
US20200064357A1 (en) 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
JP7100034B2 (ja) 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020198682A1 (en) 2019-03-28 2020-10-01 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING β-HOMOAMINO ACIDS
TW202116793A (zh) 2019-07-10 2021-05-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
US20210061872A1 (en) 2019-09-03 2021-03-04 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR20220125268A (ko) 2020-01-10 2022-09-14 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
CN118005737A (zh) 2020-01-15 2024-05-10 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
EP4188412A1 (en) 2020-07-28 2023-06-07 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3202226A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2022212698A1 (en) 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
JP2024513392A (ja) 2021-04-01 2024-03-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物
JP2024520861A (ja) 2021-06-14 2024-05-24 プロタゴニスト セラピューティクス， インコーポレイテッド 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体

Also Published As

Publication number Publication date
CA3167751A1 (en) 2021-07-22
CN118063554A (zh) 2024-05-24
AR121070A1 (es) 2022-04-13
MX2022008741A (es) 2022-10-03
CN118005736A (zh) 2024-05-10
US20210261622A1 (en) 2021-08-26
CN115298196A (zh) 2022-11-04
JP7441955B2 (ja) 2024-03-01
CN118027153A (zh) 2024-05-14
KR20220141807A (ko) 2022-10-20
CL2022001893A1 (es) 2023-03-03
EP4090670A1 (en) 2022-11-23
AU2021207653A1 (en) 2022-08-04
TW202140517A (zh) 2021-11-01
WO2021146441A1 (en) 2021-07-22
JP2023139158A (ja) 2023-10-03
DOP2022000147A (es) 2023-01-15
JP2023511552A (ja) 2023-03-20
JOP20220169A1 (ar) 2023-01-30
BR112022013957A2 (pt) 2022-10-11
ECSP22063238A (es) 2022-09-30
US11845808B2 (en) 2023-12-19
PE20230370A1 (es) 2023-03-06
US20240150405A1 (en) 2024-05-09
CN118005737A (zh) 2024-05-10
IL294680A (en) 2022-09-01
CO2022009931A2 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
JOP20220169A1 (ar) مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية
MX2022008740A (es) Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2023005994A (es) Composiciones de inhibidores peptidicos del receptor de interleucina-23.
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
WO2023288019A3 (en) Lipidated peptide inhibitors of interleukin-23 receptor
MX2020009228A (es) Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
MX2022000449A (es) Conjugados peptídicos de citotoxinas como terapéuticos.
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2022002443A (es) Compuestos inhibidores de perk.
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2
MX2021007967A (es) Inhibidores de síntesis de leucotrienos.
EA202092204A1 (ru) Композиции
LV15485A (lv) Selenofēnhromenonu hidroksāmskābes, to izgatavošana un izmantošana angioģenēzes inhibīcijā